Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

William F. Regine, Kathryn Winter, Ross A. Abrams et al. · JAMA · 2008 · 749 citations

Medicine, Oncology, Surgery +17

Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

John R. Mackey, Rajam S. Mani, M Selner et al. · PubMed · 1998 · 605 citations

Medicine, Oncology, Pharmacology +14

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

Jennifer L. Spratlin, Randeep Sangha, Darryl Glubrecht et al. · Clinical Cancer Research · 2004 · 425 citations

Medicine, Oncology, Pharmacology +13

Gemcitabine: preclinical pharmacology and mechanisms of action.

William Plunkett, Peng Huang, C. E. Searcy et al. · PubMed · 1996 · 395 citations

Medicine, Pharmacokinetics, Pharmacology +7